4.5 Article

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020

期刊

EUROSURVEILLANCE
卷 23, 期 25, 页码 2-12

出版社

EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2018.23.25.1700796

关键词

-

资金

  1. University of Antwerp scientific chair in Evidence-Based Vaccinology
  2. Pfizer
  3. GlaxoSmithKline
  4. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [682540]
  5. Hasselt University [BOF14BL07]
  6. Research Fund of Hasselt University [BOF11NI31]

向作者/读者索取更多资源

Background: Large measles and mumps outbreaks recently occurred throughout Europe and the United States. Aim: Our aim was to estimate and map the risk of resurgence for measles, mumps and rubella in France. Methods: We used a multi-cohort model combining seroprevalence information, vaccine coverage and social contact data. Results: The overall outbreak risk for France in 2018 was highest for mumps, remained significant for measles despite a recent measles outbreak and was low for rubella. Outbreak risks were heterogeneous between departments, as the effective reproduction numbers for 2018 ranged from 1.08 to 3.66. The seroprevalence, and therefore the risk of measles and rubella infection, differed significantly between mates and females. There was a lower seroprevalence, and therefore a higher risk, for males. Infants of less thane year would be seriously affected in a future outbreak of measles, mumps or rubella, but the highest overall caseload contribution would come from teenagers and young adults (10-25 years old). Conclusions: The high risk for teenagers and young adults is of concern in view of their vulnerability to more severe measles, mumps and rubella disease and complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据